SCHEMBL27697290

SCHEMBL27697290

CC(C(=O)C(C)c1cc(Br)ccc1F)c1cc(Br)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.42
APLNR P35414 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ACACB O00763 1/20 0.36
ALDH1A1 P00352 4/20 0.36
NPC1 O15118 3/20 0.36
LMNA P02545 3/20 0.36
RAB9A P51151 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.36
FPR2 P25090 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
APP P05067 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27747528 0.85 APLNR (0.48) DGAT1APLNRKDM4EACACBALDH1A1
SCHEMBL21096066 0.83 ALDH1A1 (0.41) DGAT1APLNRKDM4EACACBALDH1A1
SCHEMBL27790938 0.79 LMNA (0.38) ALDH1A1NPC1LMNARAB9ASMN1; SMN2
SCHEMBL27506947 0.79 HPGD (0.48) KDM4ELMNASMN1; SMN2KMT2AGAA
SCHEMBL1145058 0.79 GABRA1 (0.39) DGAT1APLNRKDM4EACACBNPC1
SCHEMBL31079293 0.78 GABRA1 (0.46) DGAT1APLNRKDM4EACACBALDH1A1
SCHEMBL12261433 0.78 GABRA1 (0.46) DGAT1APLNRKDM4EACACBALDH1A1
SCHEMBL27859661 0.78 APP (0.38) ALDH1A1APPCES2CES1
SCHEMBL28097423 0.78 DGAT1 (0.42) DGAT1ALDH1A1NPC1LMNARAB9A
SCHEMBL27603483 0.78 KDM4E (0.47) DGAT1KDM4ENPC1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103391928-A 1, 4-oxaza as BACE1 and/or BACE2 inhibitors HOFFMANN LA ROCHE 2013-11-13 CN disclosed
CN-103339117-A 1,4 oxazines as bace1 and/or bace2 inhibitors HOFFMANN LA ROCHE 2013-10-02 CN disclosed
CN-103328454-A 1,4 oxazines as BACE1 and/or BACE2 inhibitors HOFFMANN LA ROCHE 2013-09-25 CN disclosed
CN-103261195-A 1,2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors JANSSEN PHARMACEUTICALS INC 2013-08-21 CN disclosed
CN-103068806-A 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds SIENA BIOTECH SPA 2013-04-24 CN disclosed
CN-102958922-A 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds HOFFMANN LA ROCHE 2013-03-06 CN disclosed
CN-102803250-A 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP17 NOVARTIS AG 2012-11-28 CN disclosed
CN-102712621-A Pyrazine derivatives and their use in the treatment of neurological disorders NOVARTIS AG 2012-10-03 CN disclosed
CN-102666507-A Oxazine derivatives and their use in the treatment of neurological disorders NOVARTIS AG 2012-09-12 CN disclosed
CN-102639516-A 3-amino-5-phenyl-5, 6-dihydro-2H- [1,4] oxazine derivatives HOFFMANN LA ROCHE 2012-08-15 CN disclosed
CN-102471293-A Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders NOVARTIS AG 2012-05-23 CN disclosed
CN-101454314-A Kinase inhibitors SCHERING CORP (US) 2009-06-10 CN disclosed
CN-101389335-A Thiadiazole compounds and methods of use. AMGEN INC (US) 2009-03-18 CN disclosed
CN-101340912-A (indazol-5-yl) -pyrazines and (1, 3-dihydro-indol-2-one) -pyrazines for the treatment of RHO kinase mediated diseases and conditions ALCON MFG LTD (US) 2009-01-07 CN disclosed
CN-101146796-A 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer SCHERING CORP (US) 2008-03-19 CN disclosed